Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Stock Rated “Buy” by Sell-Side Brokerages

by · The Cerbat Gem

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI – Get Free Report) has earned a consensus rating of “Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $16.00.

Several research firms have commented on LMRI. KeyCorp initiated coverage on Lumexa Imaging in a report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. Raymond James Financial set a $17.00 target price on Lumexa Imaging in a report on Monday, September 28th. Barclays lifted their price target on Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, August 28th. Finally, Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday.

View Our Latest Stock Report on Lumexa Imaging

Lumexa Imaging Price Performance

LMRI opened at $10.32 on Monday. The business has a fifty day moving average of $11.30 and a 200 day moving average of $10.28. The stock has a market cap of $991.44 million and a P/E ratio of -21.06. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a 52-week low of $6.45 and a 52-week high of $19.45.

Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, sell-side analysts anticipate that Lumexa Imaging will post 0.25 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Lumexa Imaging in the 4th quarter worth $27,750,000. Jupiter Topco LLC purchased a new stake in Lumexa Imaging in the second quarter valued at about $24,269,000. Janus Henderson Group PLC boosted its holdings in Lumexa Imaging by 5.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock worth $18,063,000 after acquiring an additional 107,903 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Lumexa Imaging during the second quarter worth about $15,771,000. Finally, Brigade Capital Management LP acquired a new position in shares of Lumexa Imaging during the second quarter valued at about $7,511,000.

Lumexa Imaging Company Profile

(Get Free Report)

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.

Featured Articles